denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Sanofi and Incyte Corporation
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Education, Diseases, Treatment Considerations, Adverse Events
Hematology Disease Topics & Pathways:
Education, Diseases, Treatment Considerations, Adverse Events
Friday, December 6, 2024: 3:00 PM-6:00 PM
Marriott Grand Ballroom 2-4
(Marriott Marquis San Diego Marina)
Chair:
Matthew Matasar, MD, MS, Division of Blood Disorders, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
Disclosures:
Matasar: Roche: Consultancy, Honoraria, Research Funding; Regeneron Pharmaceuticals, Inc.: Honoraria; BMS/Celgene: Honoraria; Johnson & Johnson: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Kite: Honoraria; Epizyme: Honoraria; Pharmacyclics: Consultancy, Honoraria, Research Funding; Merck: Current equity holder in publicly-traded company; Pfizer: Honoraria; ADC Therapeutics: Honoraria; Genmab: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria; Seattle Genetics: Consultancy, Honoraria, Research Funding; GM Biosciences: Consultancy, Research Funding; Immunovaccine Technologies: Research Funding; Allogene: Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria, Research Funding; IMV Therapeutics: Honoraria.
Speakers:
Luciano J. Costa, MD, PhD, University of Alabama at Birmingham
,
Chaitra S. Ujjani, MD, Clinical Research Division, Fred Hutch Cancer Center; and Division of Oncology, University of Washington
,
Nisha S. Joseph, MD, Winship Cancer Institute of Emory University
and
Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc, Sir Charles Gairdner Hospital and the University of Western Australia
Disclosures:
Costa: Caribou: Research Funding; BMS: Consultancy, Honoraria, Research Funding; Genentech, Inc.: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Adaptive biotechnoligies: Honoraria; Pfizer: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria. Ujjani: AbbVie, Astrazeneca, Lilly, PCYC: Research Funding; Abbvie, Astrazeneca, Beigene, Genentech, Jansen, Lilly, Pharmacyclics: Honoraria. Joseph: AstraZeneca: Research Funding; Pfizer Oncology: Research Funding; GSK: Honoraria, Research Funding; BMS: Consultancy, Research Funding; J&J Oncology: Consultancy, Honoraria, Research Funding. Cheah: Regeneron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lilly: Other: Travel Expenses, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Genmab: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Speakers Bureau; Menarini: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Dizal: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.
This 120-minute symposium will emulate a typical day for a community hematologist/oncologist, highlighting the diversity of hematologic malignancies and the complex decisions faced daily through a series of patient cases. A panel of expert hematologist/oncologists will evaluate and discuss challenging patient scenarios using recent clinical data, treatment guidelines, and best practices to optimize access to care. The symposium will emphasize patient-centric care and shared decision-making as top priorities, addressing the practical challenges that busy community clinicians encounter. Through this focus on real-world cases and evidence-based strategies, the event aims to enhance the integration of innovative treatments and improve patient outcomes in the community setting.
See more of: Friday Satellite Symposia